Mercaptopurine
Total Payments
$1.2M
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $1.2M | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Mercaptopurine, 20MG, Fasted Pivotal | Hikma Pharmaceuticals USA | $865,801 | 0 |
| A Single-Dose, Four-Period, Two-Treatment, Full Replicate Bioequivalence Study of Mercaptopurine 20 mg/mL suspension compared to PURIXAN 20 mg/mL suspension | Hikma Pharmaceuticals USA | $311,813 | 0 |
Top Doctors Receiving Payments for Mercaptopurine
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Austin, TX | $1.2M | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 0
- Transactions 2
About Mercaptopurine
Mercaptopurine is a drug associated with $1.2M in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2021 to 2021. In 2021, $1.2M was paid across 2 transactions to 0 doctors.
The most common payment nature for Mercaptopurine is "Unspecified" ($1.2M, 100.0% of total).
Mercaptopurine is associated with 2 research studies, including "Mercaptopurine, 20MG, Fasted Pivotal" ($865,801).